# Advance market commitments for paediatric and rare cancer drugs

Source: https://onco.cc/ideas/idea-fund-amc-paediatric-rare/  
OnCo record `idea-fund-amc-paediatric-rare` (Idea). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Payers would promise in advance to buy a set number of doses at a set price for any drug that meets a defined bar in a rare or childhood cancer, so companies know the market exists before they invest.

## Summary

Modelled on Gavi's pneumococcal advance market commitment, a consortium of national payers and foundations pledges a guaranteed purchase (volume times price, for example $300 million over ten years) for the first therapy meeting a target product profile in a specified rare or paediatric indication: diffuse midline glioma, relapsed neuroblastoma, Ewing sarcoma, rare fusion-driven cancers. In exchange, the developer accepts a long-run affordable price and supply commitments. The commitment is only paid on delivery of a product that meets pre-registered efficacy criteria, so payers bear no risk of failure.

## Fields

- Kind: Idea
- Last checked: 2026-09-08
- Hypothesis: An AMC of a few hundred million dollars for a named paediatric indication brings at least two registration-intent programmes into that indication within five years where there were none, and shortens time from adult approval to paediatric labelling for eligible mechanisms.
- Rationale: The pneumococcal AMC accelerated vaccine availability in poor countries by years and drew in new manufacturers. Paediatric oncology drug development is delayed by uncertain and small markets; the RACE Act mandates studies but does not make them profitable. A guaranteed market is the missing pull.
- Proposed test: Design one AMC with a target product profile and escrowed funds for a single indication, publish it, and count programme entries and phase 1/2 starts in that indication over five years against comparable indications.
- Maturity: speculative
- Actor: payer

## Sources

- Gavi pneumococcal Advance Market Commitment: https://www.gavi.org/investing-gavi/innovative-financing/pneumococcal-amc

## Connected records

- ideas: [A non-profit pharmaceutical company for the cancers markets ignore](https://onco.cc/ideas/idea-fund-nonprofit-pharma/), [Escrow a share of adult revenue until the paediatric study is done](https://onco.cc/ideas/idea-fund-paediatric-deferral-escrow/), [Milestone-based venture philanthropy with royalties recycled into the pipeline](https://onco.cc/ideas/idea-fund-milestone-venture-philanthropy/)
- cancers: [Glioma & glioblastoma](https://onco.cc/cancers/glioblastoma/), [Neuroblastoma (paediatric)](https://onco.cc/cancers/neuroblastoma/), [Sarcomas (soft tissue, bone, GIST)](https://onco.cc/cancers/sarcoma/)
- companies: [Children's Oncology Group (COG)](https://onco.cc/companies/childrens-oncology-group/)
- bottlenecks: [Incentives reward me-too drugs and marginal gains](https://onco.cc/bottlenecks/b-incentive-misalignment/), [Rare and paediatric cancers without markets](https://onco.cc/bottlenecks/b-rare-cancers/)
- roadmaps: [Paediatric oncology roadmap: cooperative-group cures → engineered immunity → drugs developed for children first](https://onco.cc/roadmaps/paediatric-oncology-roadmap/)

---
JSON: https://onco.cc/api/v1/entities/idea-fund-amc-paediatric-rare.json